Solal-Céligny P - Search Results

1

Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance.

Cohen Y, Solal-Céligny P, Polliack A. Cohen Y, et al. Haematologica. 2003 Jul;88(7):811-23. Haematologica. 2003. PMID: 12857561 Review.

2

Safety of rituximab maintenance therapy in follicular lymphomas.

Solal-Céligny P. Solal-Céligny P. Leuk Res. 2006 Mar;30 Suppl 1:S16-21. doi: 10.1016/s0145-2126(06)80004-4. Leuk Res. 2006. PMID: 16750674 Review.

3

Rituximab therapy for indolent non-Hodgkin's lymphoma.

Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M. Hagenbeek A, et al. Anticancer Drugs. 2002 Nov;13 Suppl 2:S11-7. Anticancer Drugs. 2002. PMID: 12710586 Review.

4

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, Brousse N, Feugier P, Tilly H, Solal-Céligny P, Coiffier B. Sebban C, et al. J Clin Oncol. 2008 Jul 20;26(21):3614-20. doi: 10.1200/JCO.2007.15.5358. Epub 2008 Jun 16. J Clin Oncol. 2008. PMID: 18559872

5

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).

Morschhauser F, Mounier N, Sebban C, Brice P, Solal-Celigny P, Tilly H, Feugier P, Fermé C, Copin MC, Lamy T. Morschhauser F, et al. Cancer. 2010 Sep 15;116(18):4299-308. doi: 10.1002/cncr.25280. Cancer. 2010. PMID: 20549824 Free article. Clinical Trial.

6

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.

Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Céligny P, Barrett M, Berge C, Bittner B, Boehnke A, McIntyre C, Macdonald D. Davies A, et al. Lancet Oncol. 2014 Mar;15(3):343-52. doi: 10.1016/S1470-2045(14)70005-1. Epub 2014 Feb 10. Lancet Oncol. 2014. PMID: 24521993 Clinical Trial.

7

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P. Marcus R, et al. Blood. 2005 Feb 15;105(4):1417-23. doi: 10.1182/blood-2004-08-3175. Epub 2004 Oct 19. Blood. 2005. PMID: 15494430 Free article. Clinical Trial.

8

Maintenance therapy for low-grade lymphomas: has the time come?

Cartron G, Solal-Céligny P. Cartron G, et al. Curr Opin Oncol. 2007 Sep;19(5):425-32. doi: 10.1097/CCO.0b013e3282c9ad65. Curr Opin Oncol. 2007. PMID: 17762565 Review.

9

Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden.

Solal-Céligny P. Solal-Céligny P. Anticancer Drugs. 2001 Jun;12 Suppl 2:S11-4. Anticancer Drugs. 2001. PMID: 11508931 Review.

10

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Tilly H, Thieblemont C, Bergougnoux L, Lazreg F, Solal-Celigny P. Colombat P, et al. Ann Oncol. 2012 Sep;23(9):2380-2385. doi: 10.1093/annonc/mds177. Epub 2012 Jul 10. Ann Oncol. 2012. PMID: 22782332 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters